Purpose of review: Prostaglandin analogs (PGAs) are the most widely used ocular hypotensive medications. Half of the patients with glaucoma and 40% of patients with ocular hypertension require more than one medication to sufficiently lower their intraocular pressures (IOPs). Therefore, it is important to understand the varying efficacy of adjunctive therapies currently available for use in combination with PGAs.
Recent findings: The IOP-lowering efficacy and safety profiles of various adjunctive treatments continue to be better elucidated, including the nocturnal IOP-lowering efficacy of various medication classes and laser trabeculoplasty.
Summary: For patients already on a PGA, the mean diurnal IOP-lowering achieved with the addition of an alpha2 adrenergic agonist, a beta adrenergic antagonist, or a topical carbonic anhydrase inhibitor is similar, whereas the side-effect profiles, nocturnal IOP-lowering efficacy, and trough IOP-lowering effects vary. Laser trabeculoplasty is also an effective means of further lowering the IOP in patients on a PGA.